It’s always rewarding to start new collaborations and recharge by getting to know like-minded people. Association for Research in Vision and Ophthalmology (ARVO) is the largest and most respected eye and vision research organization in the world, and we are happy to announce that our team members at SigmaDrugs: Andrea Fekete, MD, DSc, Judit Hodrea, PhD and Illes Kovacs MD, PhD will be also attending the Annual Meeting of ARVO and presenting our latest result on:
Sigma-1 receptor agonist ameliorates trabecular meshwork fibrosis by modulating extracellular matrix remodeling and increasing nitric oxide production.
The ARVO Annual Meeting is the premiere gathering for eye and vision scientists at all career stages, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. The theme of the 2023 Annual Meeting speaks to the mechanistic diversity in ocular disease, plus how we, as vision scientists, are a diverse group with multiple backgrounds and perspectives.
This year’s meeting is in New Orleans from April 23 to 27 at the Ernest N. Morial Convention Center. This fantastic city is replete with old-world charm and ambiance.
About our poster: Abstract title: Sigma-1 receptor agonist ameliorates trabecular meshwork fibrosis by modulating extracellular matrix remodeling and increasing nitric oxide production
Judit Hodrea 1,2, Minh N. Tran 1,2, Balazs Besztercei 3, Timea Medveczki1,2, Illes Kovacs 4,5, Xavier Gasull 6, Attila J. Szabo 2, Andrea Fekete 1,2
Purpose: Maintenance of normal tissue homeostasis in the trabecular meshwork (TM) is crucial for undisturbed aqueous humor drainage and consequently unaltered intraocular pressure (IOP). Fibrotic-like changes such as accumulation of extracellular matrix (ECM) components, result in altered stiffness and impaired outflow leading to increased IOP, which is the main risk factor of glaucoma. Thus, anti-fibrotic drugs could be novel therapeutics for glaucoma. Nitric oxide (NO) has been recognized as an important regulator of TM outflow and maintain IOP. Recently, we reported that fluvoxamine (FLU), a potent sigma-1 receptor (S1R) agonist, decreases the levels of key elements of fibrosis in the kidney and in lung. Therefore, here we investigated the antifibrotic effectiveness of FLU in mouse and human TM cells.
Presentation Type: Poster Session
Session Number: 372
Session Title: Aqueous humor dynamics, trabecular meshwork and ciliary body 2
Session Date/Times: April 25, 2023 from 3:30 PM to 5:30 PM
Schedule at a glance:
Participating in ARVO2023? Want to discuss our latest research results? Schedule a meeting with Andrea Fekete! 🔗📅 andrea.fekete@sigmadrugs.com Stay tuned to get more updates and hope to see you there!